The service will be offered via telemedicine for all Vivos-trained dental professionals to use as a therapeutic protocol in tandem with the Vivos System.
Vivos Therapeutics Inc, a medical technology company focused treatments for patients suffering from sleep-disordered breathing, announced that it will launch a new service called MyoCorrect, where trained therapists will provide Vivos-trained providers access to orofacial myofunctional therapy (OMT) via telemedicine technology as a component to obstructive sleep apnea (OSA) treatment using the company’s Vivos System.
Vivos believes the MyoCorrect service will become an important value-added component in the treatment of OSA using the Vivos System, which includes oral appliances.
According to the company, OMT therapists work to strengthen and improve function in the muscles of the lips, tongue, cheeks, and face and their related roles in breathing, sucking, chewing, swallowing, and some aspects of speech. Research has reportedly shown OMT to be an effective component of OSA treatment. Vivos plans to make the MyoCorrect protocol available as a component of the Vivos System and will actively integrate training and implementation protocols for Vivos trained dental professionals to utilize the MyoCorrect therapy.
The company says that Vivos-trained dental professionals who have actively incorporated OMT into their Vivos System treatment protocols report four primary benefits: higher case acceptance, better patient compliance, shorter treatment times, and improved clinical outcomes. However, due to a reported scarcity of trained OMT therapists in many areas and other factors, too few dental professionals and patients have been able to access this adjunctive therapy. Vivos Therapeutics says that it will provide every Vivos dental professional with immediate access via telemedicine to this clinical resource at “an attractive price point.”
“The launch of this new service is an important step for Vivos as we continue to offer what we believe are the best therapeutic options available for patients who suffer from sleep disordered breathing and the most prevalent forms of obstructive sleep apnea. We believe we will be able to leverage our current infrastructure and growing dentist network for rapid deployment and adoption of the MyoCorrect OMT therapy,” said Kirk Huntsman, chairman and CEO. “As Vivos-trained dentists come to experience the ways in which OMT can enhance their Vivos System case outcomes, we expect the adoption rate of MyoCorrect as an integral part of the Vivos System to rise. As that happens, the revenue contributions of MyoCorrect to Vivos in the form of increased Vivos System sales as well as fees charged for the OMT service could be significant.”
“We look forward to rolling out MyoCorrect across our network in the coming months,” continued Huntsman. “We believe this clinical enhancement to our flagship Vivos System treatment for mild-to-moderate OSA will work synergistically within the emerging Vivos dental sleep medicine ecosystem. This ecosystem features extensive clinical training through the Institute for Craniofacial Sleep Medicine, Vivos AireO2 practice management software, Vivos Airway Intelligence Services, Vivos Billing Intelligence Services, VivoScore diagnostic devices powered by SleepImage, our proprietary Vivos System oral appliance therapy, and multi-disciplinary collaboration between physicians and Vivos dentists through the growing network of Vivos-trained dentist offices and Pneusomnia clinics.”